Sunbelt Securities Inc. Sells 124 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sunbelt Securities Inc. lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 20.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 468 shares of the medical device company’s stock after selling 124 shares during the quarter. Sunbelt Securities Inc.’s holdings in DexCom were worth $65,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. DSM Capital Partners LLC acquired a new position in shares of DexCom during the fourth quarter worth approximately $28,000. Riverview Trust Co bought a new position in shares of DexCom in the first quarter valued at $32,000. Valley National Advisers Inc. grew its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. MV Capital Management Inc. increased its position in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares in the last quarter. Finally, Smithfield Trust Co raised its holdings in shares of DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $113.38 on Monday. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The stock’s fifty day moving average price is $123.14 and its two-hundred day moving average price is $125.73. The firm has a market cap of $45.09 billion, a PE ratio of 73.15, a PEG ratio of 2.77 and a beta of 1.22.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, equities research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,735 shares of company stock valued at $7,619,347. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on DXCM. UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Raymond James increased their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Royal Bank of Canada initiated coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Finally, Redburn Atlantic assumed coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $140.33.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.